Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Assets Average (2016 - 2026)

Akebia Therapeutics has reported Assets Average over the past 10 years, most recently at $370.4 million for Q4 2025.

  • Quarterly Assets Average rose 73.14% to $370.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $370.4 million through Dec 2025, up 73.14% year-over-year, with the annual reading at $298.6 million for FY2025, 29.17% up from the prior year.
  • Assets Average was $370.4 million for Q4 2025 at Akebia Therapeutics, up from $354.9 million in the prior quarter.
  • Over five years, Assets Average peaked at $636.4 million in Q1 2021 and troughed at $213.7 million in Q3 2024.
  • The 5-year median for Assets Average is $341.4 million (2025), against an average of $383.0 million.
  • Year-over-year, Assets Average crashed 50.11% in 2023 and then surged 73.14% in 2025.
  • A 5-year view of Assets Average shows it stood at $565.8 million in 2021, then fell by 29.28% to $400.2 million in 2022, then crashed by 40.44% to $238.4 million in 2023, then fell by 10.26% to $213.9 million in 2024, then surged by 73.14% to $370.4 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Assets Average are $370.4 million (Q4 2025), $354.9 million (Q3 2025), and $327.9 million (Q2 2025).